About The Study: In a randomized clinical trial with 104 participants, psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events. These findings add to increasing evidence that psilocybin—when administered with psychological support—may hold promise as a novel intervention for major depressive disorder. Authors: Charles L. Raison, M.D., of Usona Institute in Fitchburg, Wisconsin, is the corresponding author.

https://www.miragenews.com/single-dose-psilocybin-therapy-tackles-major-1075715/

#miragenews